1. Catalog
  2. Nodes
  3. composite(a(CHEBI:Anatabine), a(CHEBI:lipopolysaccharide))

composite(a(CHEBI:Anatabine), a(CHEBI:lipopolysaccharide))

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Components

Appears in Networks 1

Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation v1.0.0

In-Edges 0

Out-Edges 9

composite(a(CHEBI:Anatabine), a(CHEBI:lipopolysaccharide)) hasComponent a(CHEBI:Anatabine) View Subject | View Object

Appears in Networks:

composite(a(CHEBI:Anatabine), a(CHEBI:lipopolysaccharide)) hasComponent a(CHEBI:lipopolysaccharide) View Subject | View Object

Appears in Networks:

composite(a(CHEBI:Anatabine), a(CHEBI:lipopolysaccharide)) decreases p(MGI:Il1b) View Subject | View Object

Our results showed that intraperitoneal injection of LPS (1 mg/kg) caused a significant elevation of plasma IL-1b (Mann–Whitney U=3, Z=-2.988, P=0.003), IL-6 (Mann–Whitney U=0, Z=-3.366, P=0.001) and TNFa (Mann– Whitney U=0, Z=-3.508, P<0.001) 4 h after the LPS challenge whereas in mice co-treated with an intraperitoneal injection of anatabine (2 mg/kg) and LPS, a significant reduction in plasma IL-1b (Mann–Whitney U=7, Z=-2.645, P=0.008) and TNFa (Mann–Whitney U=4, Z=-2.941, P=0.003) levels was observed (Fig. 6) PubMed:23178521

Appears in Networks:
Annotations
MeSH
Plasma

composite(a(CHEBI:Anatabine), a(CHEBI:lipopolysaccharide)) decreases p(MGI:Il1b) View Subject | View Object

Anatabine significantly inhibited LPS induced IL-6 (Mann–Whitney U=4, Z=-3.303, P=0.001), TNF-a (Mann–Whitney U=0, Z=-3.361, P=0.001) and IL-1b levels in the spleen (Mann–Whitney U=9, Z=-1.981, P=0.048) (Fig. 7) PubMed:23178521

Appears in Networks:
Annotations
MeSH
Spleen

composite(a(CHEBI:Anatabine), a(CHEBI:lipopolysaccharide)) decreases p(MGI:Tnf) View Subject | View Object

Our results showed that intraperitoneal injection of LPS (1 mg/kg) caused a significant elevation of plasma IL-1b (Mann–Whitney U=3, Z=-2.988, P=0.003), IL-6 (Mann–Whitney U=0, Z=-3.366, P=0.001) and TNFa (Mann– Whitney U=0, Z=-3.508, P<0.001) 4 h after the LPS challenge whereas in mice co-treated with an intraperitoneal injection of anatabine (2 mg/kg) and LPS, a significant reduction in plasma IL-1b (Mann–Whitney U=7, Z=-2.645, P=0.008) and TNFa (Mann–Whitney U=4, Z=-2.941, P=0.003) levels was observed (Fig. 6) PubMed:23178521

Appears in Networks:
Annotations
MeSH
Plasma

composite(a(CHEBI:Anatabine), a(CHEBI:lipopolysaccharide)) decreases p(MGI:Tnf) View Subject | View Object

Anatabine significantly inhibited LPS induced IL-6 (Mann–Whitney U=4, Z=-3.303, P=0.001), TNF-a (Mann–Whitney U=0, Z=-3.361, P=0.001) and IL-1b levels in the spleen (Mann–Whitney U=9, Z=-1.981, P=0.048) (Fig. 7) PubMed:23178521

Appears in Networks:
Annotations
MeSH
Spleen

composite(a(CHEBI:Anatabine), a(CHEBI:lipopolysaccharide)) decreases p(MGI:Tnf) View Subject | View Object

A significant reduction in TNF-a (Mann–Whitney U=12, Z=-2.309, P=0.021) but no significant reduction in IL-6 levels (Mann–Whitney U=25, Z=-1.223, P=0.221) or IL-1b (Mann–Whitney U=8, Z=-1.857,P=0.063) were observed in the kidney of LPS and anatabine cotreated animals (data not shown) PubMed:23178521

Appears in Networks:
Annotations
MeSH
Kidney

composite(a(CHEBI:Anatabine), a(CHEBI:lipopolysaccharide)) decreases p(MGI:Il6) View Subject | View Object

Plasma IL-6 levels show a trend for a reduction but were not significantly affected (Mann–Whitney U=19, Z=-1.368, P=0.171) by the anatabine treatment (Fig. 6) PubMed:23178521

Appears in Networks:
Annotations
MeSH
Plasma

composite(a(CHEBI:Anatabine), a(CHEBI:lipopolysaccharide)) decreases p(MGI:Il6) View Subject | View Object

Anatabine significantly inhibited LPS induced IL-6 (Mann–Whitney U=4, Z=-3.303, P=0.001), TNF-a (Mann–Whitney U=0, Z=-3.361, P=0.001) and IL-1b levels in the spleen (Mann–Whitney U=9, Z=-1.981, P=0.048) (Fig. 7) PubMed:23178521

Appears in Networks:
Annotations
MeSH
Spleen

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.